| Source | M.W. | 406.48 | CAS No. | 1062368-24-4 | |
|---|---|---|---|---|---|
| Structural Info |  |
||||
| Formulation | Powder | ||||
| Reconstitution | Before reconstitution, we recommend a brief spin to drive down any material dislodged from the bottom of the tube. The compound is soluble in DMSO. | ||||
| Stability | The powder is stable for at least 2 year if stored at -20 °C. The dissolved compound is stable for at least 1 month at 4 °C, but should be stored in aliquots at -20 °C for longer term. Protect from light. | ||||
| Purity | Greater than 98% as determined by LC/MS analysis. LC/MS and/or NMR data available upon request. | ||||
| Biological Activity | |||||
| Country of Origin | USA | ||||
A selective inhibitor of bone morphogenetic protein (BMP) type I receptors (ALK-2 and ALK-3). Only weakly inhibits ALK-4,
-5, and -7.
4-[6-(4-Piperazin-1-yl-phenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline
Ref: Cuny, G.D., et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett 18: 4388-92, 2008.